Company intelligence / Profile preview

The Campground

Cambridge, Massachusetts, United Statesparks.ny.gov ↗

Ownership: Private
Employees: ~55
Development stage: Commercial

Overview

CAMP4’s lead candidate CMP-CPS-001, an antisense oligonucleotide for urea cycle disorders, is currently in Phase 1 trials. The company also has preclinical programs targeting SYNGAP1-related neurodevelopmental disorders. Early clinical results are pending; the platform enables rapid generation of RNA-targeting therapeutics for genetic diseases.

Therapeutic areas: Metabolic DisordersNeurology
Modalities: Antisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

Alnylam PharmaceuticalsBiogenBioMarin Pharmaceutical

Beyond the preview

Go deeper on The Campground.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Campground.

Explore the full profile